Kukje Pharma Co., Ltd.

KOSE:A002720 Stock Report

Market Cap: ₩100.0b

Kukje Pharma Past Earnings Performance

Past criteria checks 0/6

Kukje Pharma's earnings have been declining at an average annual rate of -25.7%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 4.3% per year.

Key information

-25.7%

Earnings growth rate

-25.7%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate4.3%
Return on equity-9.9%
Net Margin-6.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up

Mar 20
Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up

Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals

Mar 20
Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals

If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today

Mar 19
If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today

These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well

Feb 21
These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well

What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?

Jan 25
What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?

Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec 30
Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%

Dec 04
Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%

Revenue & Expenses Breakdown
Beta

How Kukje Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A002720 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23135,373-8,41565,4502,646
30 Sep 23131,005-9,25962,0262,614
30 Jun 23129,044-5,20957,3852,243
31 Mar 23125,7402,24454,9162,141
31 Dec 22126,5833,55754,8051,967
30 Sep 22128,5561,44656,4322,411
30 Jun 22128,22779555,9622,873
31 Mar 22125,612-26555,2242,927
31 Dec 21119,746-1,55952,2492,772
30 Sep 21115,090-1,88250,3752,491
30 Jun 21118,750-2,01951,0722,380
31 Mar 21124,741-1,84655,0442,361
31 Dec 20130,3952,20354,7523,037
30 Sep 20131,5375,34352,5943,276
30 Jun 20124,1235,50949,4563,153
31 Mar 20117,305-1,88844,5023,025
31 Dec 19111,122-4,76143,9612,604
30 Sep 19101,855-3,84843,3192,412
30 Jun 19103,493-3,42242,7152,806
31 Mar 19104,4773,23341,5673,074
31 Dec 18107,6812,19341,6113,592
30 Sep 18117,4961,09240,4844,224
30 Jun 18122,58069642,6193,620
31 Mar 18123,9671,34044,1803,366
31 Dec 17123,3101,09245,3633,291
30 Sep 17122,1382,18945,6542,442
30 Jun 17119,2131,13445,5512,230
31 Mar 17120,52985647,6442,095
31 Dec 16120,68477348,0811,331
30 Sep 16120,507-6,75649,2971,043
30 Jun 16117,332-7,30549,0401,087
31 Mar 16116,753-5,95247,924895
31 Dec 15117,637-5,94349,0431,066
30 Sep 15119,233-6,11749,7041,721
30 Jun 15123,754-4,18250,0061,786
31 Mar 15123,037-5,39948,0661,593
31 Dec 14122,426-6,93246,4471,534
30 Sep 14123,2612,59344,2161,424
30 Jun 14121,53340944,5211,155
31 Mar 14120,46290944,2911,137
31 Dec 13120,4612,12545,292817
30 Sep 13113,964-8,36744,9911,027
30 Jun 13115,836-8,39345,1771,027

Quality Earnings: A002720 is currently unprofitable.

Growing Profit Margin: A002720 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A002720 is unprofitable, and losses have increased over the past 5 years at a rate of 25.7% per year.

Accelerating Growth: Unable to compare A002720's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A002720 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).

Return on Equity

High ROE: A002720 has a negative Return on Equity (-9.91%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.